Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Recruiting

QUTENZAObservational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Sponsor:

Averitas Pharma, Inc.

Code:

NCT06495424

Conditions

Peripheral Diabetic Neuropathy

Painful Diabetic Neuropathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Capsaicin 8%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-27. This information was provided to ClinicalTrials.gov by Averitas Pharma, Inc. on 2025-12-17.